Immunogenomics

Next Generation Technologies to explore and apply the Adaptive Immune System

Millions of unique T- and B-cell receptor gene combinations are the basis of the extremely complex adaptive immune system. New technologies such as Next Generation Sequencing, artificial intelligence, synthetic biology, and nanoparticle-based delivery methods enable both, biomarker and target discovery, as well as immunotherapy approaches to fight cancer & autoimmune and other diseases:

Bulk TCR and BCR Sequencing – Immune Repertoire Profiling

Use immune samples such as blood, PBMCs, isolated T or B cells, tumor biopsies, or tissue including FFPE samples, to identify and quantify TCR and BCR clonotypes by a combination of Multiplex PCR and Next Generation Sequencing.

Single Cell TCR and BCR Sequencing – Chain Pairing Assays

Single-cell adaptive immune receptor repertoire sequencing (scAIRR-seq) enables to access the nucleotide sequences of paired receptor chains from T-cell receptors (TCR) or B-cell receptors (BCR ), which is crucial to explore the diversity of immune cells in depth and is necessary to clone functional TCRs resp. antibodies for antigen discovery studies and the development of T Cell- or antibody-based therapies

Receptor Chain Synthesis and Cloning – TCR and BCR Chain Expression

Cell System to assess TCR – Antigen Interactions

Engineered Jurkat T-Cell Receptor (TCR) Knockout Reporter Cells and K562 Antigen Presenting Cells (APC) facilitating epitope discovery and validation of predicted TCR-antigen specificity.

Express target TCR α/β pair sequences in Cellecta’s Jurkat TCR KO GFP Reporter Cells to screen across multiple antigens, and pinpoint specific reactivity by co-culturing with K562 APC Cells presenting
peptide–MHC complexes, or alternatively by dextramer staining.

Synthetic mRNAs – Expression of Antibody-, CAR- and ADC- Targets & Reporter Genes

circRNA and saRNA synthesis – High Expression of Targets

LNPs (Lipid Nano Particles) – RNA Delivery